CIK 0001080014 · Large accelerated filer
Innoviva, Inc.
Sign in to watch- Ticker
- INVA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943265960
- Phone
- 6502389600
- Business address
- 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME, CA, 94010
- Former names
- THERAVANCE INC, ADVANCED MEDICINE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-20 | Zhen Marianne Chief Accounting Officer | Shares withheld for taxes | −1,127 | $21.00 | $24K | 56,389 |
| 2026-08-20 | Basso Stephen Chief Financial Officer | Shares withheld for taxes | −558 | $21.00 | $12K | 88,013 |
| 2026-08-20 | Raifeld Pavel Chief Executive Officer | Shares withheld for taxes | −1,130 | $21.00 | $24K | 284,799 |
| 2026-05-20 | Basso Stephen Chief Financial Officer | Shares withheld for taxes | −559 | $22.24 | $12K | 88,571 |
| 2026-05-20 | Raifeld Pavel Chief Executive Officer | Shares withheld for taxes | −1,130 | $22.24 | $25K | 285,929 |
| 2026-05-20 | Zhen Marianne Chief Accounting Officer | Shares withheld for taxes | −1,127 | $22.24 | $25K | 57,516 |
| 2026-05-18 | Linden Josephine Director | Grant or award | +5,733 | 5,733 | ||
| 2026-05-18 | Linden Josephine Director | Grant or award | +9,461 | 15,194 | ||
| 2026-05-18 | Linden Josephine Director | Grant or award · Non-statutory Stock Option | +9,166 | 9,166 | ||
| 2026-05-15 | Basso Stephen Chief Financial Officer | Grant or award | +1,123 | 89,130 | ||
| 2026-05-15 | Raifeld Pavel Chief Executive Officer | Grant or award | +1,123 | 287,059 | ||
| 2026-05-04 | DiPaolo Mark Director | Grant or award | +9,786 | 140,492 | ||
| 2026-05-04 | DiPaolo Mark Director | Grant or award · Non-statutory Stock Option | +10,000 | 10,000 | ||
| 2026-05-04 | Raifeld Pavel Chief Executive Officer | Grant or award | +126,646 | 285,936 | ||
| 2026-05-04 | Raifeld Pavel Chief Executive Officer | Grant or award · Non-statutory Stock Option | +312,500 | 312,500 | ||
| 2026-05-04 | Zhen Marianne Chief Accounting Officer | Grant or award | +12,766 | 58,643 | ||
| 2026-05-04 | Zhen Marianne Chief Accounting Officer | Grant or award · Non-statutory Stock Option | +31,500 | 31,500 | ||
| 2026-05-04 | Schlesinger Sarah J. Director | Grant or award | +9,786 | 140,492 | ||
| 2026-05-04 | Schlesinger Sarah J. Director | Grant or award · Non-statutory Stock Option | +10,000 | 10,000 | ||
| 2026-05-04 | Basso Stephen Chief Financial Officer | Grant or award | +37,994 | 88,007 |
Page 1 of 10 · 181 trades